Padmanee Sharma

Oncology · 2011–2023

A researcher in the Science corpus: 22 papers; trusts 9 researchers and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 440 citations into it; #351 of 1,698 by trust here, #39 by citations
• Immunology — 306 citations into it; #553 of 2,160 by trust here, #216 by citations

Whom Padmanee Sharma trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Pardoll
2. C. Robert
3. S. Rosenberg
4. F. Hodi
5. J. Wolchok
6. G. Freeman
7. Jie Yang
8. Sergio A. Quezada
9. S. Topalian
10. M. Postow

Who trusts Padmanee Sharma overall

1. Hazem E. Ghoneim
2. S. Farkona
3. Yuanyuan Zhang
4. Chunbai He
5. Yiping Fan
6. Michael S. Rooney
7. Eleftherios P. Diamandis
8. F. Greten
9. Kristen E. Pauken
10. Ruixue Huang

Papers from Padmanee Sharma's perspective

Ordered by how strongly the researchers Padmanee Sharma trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (Journal of Experimental Medicine)
3. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (Science)
4. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
5. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
6. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
7. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (New England Journal of Medicine)
8. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
9. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
10. The B7 family revisited. (Annual Review of Immunology)

Their papers

• The Human Cell Atlas (2017) — 1,788 citations
• Immune checkpoint therapy-current perspectives and future directions. (2023) — 935 citations
• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) — 793 citations
• Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) — 1,356 citations
• B cells and tertiary lymphoid structures promote immunotherapy response (2020) — 2,250 citations
• Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma (2018) — 754 citations
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018) — 3,808 citations
• Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) — 653 citations
• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. (2017) — 1,512 citations
• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017) — 775 citations
• Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade (2017) — 1,153 citations
• Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade (2016) — 871 citations
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) — 1,151 citations
• Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy (2016) — 1,192 citations
• The future of immune checkpoint therapy (2015) — 4,384 citations
• Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015) — 2,204 citations
• Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (2015) — 5,232 citations
• Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. (2015) — 1,337 citations
• Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities (2015) — 835 citations
• Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Diminished Survival (2014) — 1,602 citations